Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc…
Today BIO’s David Thomas and Chad Wessel have put some much-needed light onto the biotech investor trends over the past decade with a newly released report (http://bio.org/biovcstudy).
